Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

被引：0

作者：

Montalban-Bravo, Guillermo ^{[1
]}

Short, Nicholas J. ^{[1
]}

Chien, Kelly S. ^{[1
]}

Valero, Yesid Alvarado ^{[1
]}

Daver, Naval ^{[1
]}

Borthakur, Gautam ^{[1
]}

Swaminathan, Mahesh ^{[1
]}

Maiti, Abhishek ^{[2
]}

Hammond, Danielle E. ^{[1
]}

Nogueras-Gonzalez, Graciela ^{[3
]}

Huang, Xuelin ^{[3
]}

Schneider, Heather ^{[4
]}

Shelly, Kristen ^{[4
]}

Kadia, Tapan M. ^{[1
]}

Kantarjian, Hagop M. ^{[4
]}

Garcia-Manero, Guillermo ^{[5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Bataller, Alex
Montalban-Bravo, Guillermo
Bazinet, Alexandre
Alvarado, Yesid
Chien, Kelly
Venugopal, Sangeetha
Ishizawa, Jo
Hammond, Danielle
Swaminathan, Mahesh
Sasaki, Koji
Issa, Ghayas C.
Short, Nicholas J.
Masarova, Lucia
Daver, Naval G.
Kadia, Tapan M.
Colla, Simona
Qiao, Wei
Huang, Xuelin
Kanagal-Shamanna, Rashmi
Hendrickson, Stephany
Ravandi, Farhad
Jabbour, Elias
Kantarjian, Hagop
Garcia-Manero, Guillermo
LANCET HAEMATOLOGY, 2024, 11 (03): : e186 - e195
[22] Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Garcia-Manero, Guillermo
Gore, Steven D.
Cogle, Christopher
Ward, Renee
Shi, Tao
MacBeth, Kyle J.
Laille, Eric
Giordano, Heidi
Sakoian, Sarah
Jabbour, Elias
Kantarjian, Hagop
Skikne, Barry
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2521 - 2527
[23] Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
Kenealy, Melita
Patton, Nigel
Filshie, Robin
Nicol, Andrew
Ho, Shir-Jing
Hertzberg, Mark
Mills, Tony
Prosser, Ian
Link, Emma
Cowan, Linda
Zannino, Diana
Seymour, John F.
LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 298 - 307
[24] A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Sekeres, Mikkael A.
Schuster, Michael W.
Joris, Magalie
Krauter, Jurgen
Maertens, Johan A.
Gyan, Emmanuel
Kovacsovics, Tibor
Verma, Amit
Vyas, Paresh
Wang, Eunice S.
Ma, Weidong Wendy
Zeremski, Mirjana
Kudla, Arthur
Chan, Geoffrey
Zeidan, Amer M.
BLOOD, 2019, 134
[25] A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia
Bazinet, Alexandre
Kantarjian, Hagop
Borthakur, Gautam
Yilmaz, Musa
Bose, Prithviraj
Jabbour, Elias
Alvarado, Yesid
Chien, Kelly
Pemmaraju, Naveen
Takahashi, Koichi
Short, Nicholas
Daver, Naval
Issa, Ghayas
Jain, Nitin
Bull-Linderman, Debra
DiNardo, Courtney
Montalban-Bravo, Guillermo
Garcia-Manero, Guillermo
Sasaki, Koji
Ravandi, Farhad
Kadia, Tapan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S239 - S240
[26] FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE
Madry, K.
Lis, K.
Zurawska, J.
Gorka, M.
Kacprzyk, P.
Dutka, M.
Rodzaj, M.
Bolkun, L.
Krochmalczyk, D.
Drozd-Sokolowska, J.
Waszczuk-Gajda, A.
Knopinska-Posluszny, W.
Kopinska, A.
Subocz, E.
Masternak, A.
Guzicka-Kazimierczak, R.
Gil, L.
Machowicz, R.
Dwilewicz-Trojaczek, J.
HAEMATOLOGICA, 2017, 102 : 490 - 490
[27] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Desikan, Sai Prasad Prasad
Montalban-Bravo, Guillermo
Ohanian, Maro
Daver, Naval
Yilmaz, Musa
Konopleva, Marina
Kadia, Tapan M.
Venugopal, Sangeetha
Schneider, Heather
Chien, Kelly S.
Kanagal-Shamanna, Rashmi
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD, 2021, 138 : 3704 - +
[28] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
Garcia, Jacqueline S.
Platzbecker, Uwe
Odenike, Olatoyosi
Fleming, Shaun
Fong, Chun Yew
Cook, Rachel
Jacoby, Meagan
Nowak, Daniel
Chyla, Brenda
Zhou, Ying
Ku, Grace
Potluri, Jalaja
Garcia-Manero, Guillermo
BLOOD, 2023, 142
[29] The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
Garcia, Jacqueline S.
Wei, Andrew H.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nolte, Florian
Peterlin, Pierre
Jurcic, Joseph
Jacoby, Meagan
Hong, Wen-Jen
Platzbecker, Uwe
Odenike, Olatoyosi
Cunningham, Ilona
Zhou, Ying
Dunbar, Martin
Harb, Jason G.
Popovic, Relja
Tanwani, Poonam
Gopalakrishnan, Sathej
Wolff, Johannes
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S315 - S316
[30] Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
Wei, Andrew H.
Garcia, Jacqueline S.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nowak, Daniel
Peterlin, Pierre
Jurcic, Joseph
Jacoby, Meagan A.
Platzbecker, Uwe
Odenike, Olatoyosi
Cunningham, Ilona
Zhou, Ying
Hoffman, David
Hogdal, Leah
Naqvi, Kiran
Kye, Steve
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S343

← 1 2 3 4 5 →